Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-08-16Clinical Trial Update: Persistence Targeted Smoking Cessation in Serious Mental Illness (SMI) [NA]
A completed clinical trial on persistence-targeted smoking cessation in individuals with serious mental illness has posted results as of 202…
-
FDA approval · 2022-08-15FDA Approved: QUETIAPINE — Original Application (BluePoint Laboratories)
FDA approved a generic version of quetiapine from BluePoint Laboratories under an Original Application (ANDA 215478).
-
CLINICAL_TRIALS trial_result · 2022-08-03Clinical Trial Update: Stimulating the Brain to Improve Self-Awareness [NA]
A completed clinical trial on brain stimulation to improve self-awareness in schizophrenia and schizoaffective disorder, with results posted…
-
FDA approval · 2022-07-29FDA Approved: INVEGA SUSTENNA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for INVEGA SUSTENNA (paliperidone palmitate) from Janssen Pharmaceuticals, Inc.
-
FDA approval · 2022-07-13FDA Approved: OLANZAPINE — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for olanzapine filed by Torrent Pharmaceuticals Limited.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-07-08FDA Approved: OLANZAPINE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application from Apotex Corp. for olanzapine, authorizing a generic olanzapine product.
-
CLINICAL_TRIALS trial_result · 2022-07-07Clinical Trial Update: Non-Invasive Direct Current Stimulation for Cognition in Schizophrenia [NA]
A terminated clinical trial investigating non-invasive direct current stimulation for cognition in schizophrenia/psychosis; results posted i…
-
FDA approval · 2022-06-16FDA Approved: QUETIAPINE FUMARATE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' generic quetiapine fumarate under an Original Application. The product will be used for the same indica…
-
CLINICAL_TRIALS trial_result · 2022-06-14Clinical Trial Update: D-serine Augmentation of Neuroplasticity [Phase 1, Phase 2]
Phase 1/2 trial updates on D-serine augmentation to enhance neuroplasticity in schizophrenia and schizoaffective disorder; study completed w…
-
CLINICAL_TRIALS trial_result · 2022-06-08Clinical Trial Update: Effects of Galantamine on Cognition [Phase 2]
Phase 2 trial investigating the effects of galantamine on cognition in schizophrenia has completed with results posted.
-
FDA approval · 2022-05-27FDA Approved: ARIPIPRAZOLE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for aripiprazole filed by Amneal Pharmaceuticals LLC (generic aripiprazole).
-
CLINICAL_TRIALS trial_result · 2022-05-23Clinical Trial Update: Research Into Antipsychotic Discontinuation and Reduction Trial [Phase 4]
Phase 4 trial updating research on discontinuation and reduction strategies for antipsychotics in schizophrenia-spectrum disorders.
-
FDA approval · 2022-05-18FDA Approved: PERPHENAZINE — Original Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved an original application for a generic Perphenazine (PERPHENAZINE) from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals…
-
CLINICAL_TRIALS trial_result · 2022-05-17Clinical Trial Update: Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1 [Phase 2]
Phase 2 trial of targeted pharmacological and behavioral treatments for tobacco dependence in schizophrenia has been terminated with results…
-
CLINICAL_TRIALS trial_result · 2022-04-29Clinical Trial Update: Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia [NA]
A terminated clinical trial investigating the effects of transdermal nicotine on response inhibition to emotional cues in schizophrenia.
-
CLINICAL_TRIALS trial_result · 2022-04-27Clinical Trial Update: Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia [Phase 2]
Phase 2 safety and biomarker study of RL-007 in subjects with schizophrenia completed.
-
CLINICAL_TRIALS trial_result · 2022-04-27Clinical Trial Update: Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder. [Phase 2]
Phase 2 trial evaluating sodium benzoate and/or N-acetylcysteine added to treatment as usual in early schizophrenia spectrum disorders has c…
-
FDA approval · 2022-04-26FDA Approved: CAPLYTA — Supplemental Application (Intra-Cellular Therapies, Inc)
The FDA approved a supplemental application for CAPLYTA (lumateperone) from Intra-Cellular Therapies, Inc. The approval expands the drug’s l…
-
FDA approval · 2022-04-26FDA Approved: QUETIAPINE — Original Application (Solco Healthcare U.S., LLC)
The FDA approved the original application for generic quetiapine from Solco Healthcare U.S., LLC.
-
CLINICAL_TRIALS trial_result · 2022-04-19Clinical Trial Update: Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness [NA]
Clinical trial investigating integrated smoking cessation treatment for individuals with serious mental illness completed with results poste…
-
FDA approval · 2022-04-14FDA Approved: FLUPHENAZINE HYDROCHLORIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved an original ANDA for fluphenazine hydrochloride from Sun Pharmaceutical Industries, Inc., confirming a generic formulation.
-
CLINICAL_TRIALS trial_result · 2022-04-11Clinical Trial Update: Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia [Phase 4]
Phase 4 trial comparing oral risperidone to injectable paliperidone palmitate for first-episode schizophrenia has completed.
-
FDA approval · 2022-04-05FDA Approved: IGALMI — Original Application (BioXcel Therapeutics, Inc.)
FDA approves IGALMI (dexmedetomidine) by BioXcel Therapeutics for the acute treatment of agitation in adults with schizophrenia or bipolar I…
-
CLINICAL_TRIALS trial_result · 2022-04-04Clinical Trial Update: This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months [Phase 2]
Phase 2 trial in schizophrenia evaluating tolerability and efficacy of BI 409306 over 6 months; the study was terminated and results have be…
-
FDA approval · 2022-04-01FDA Approved: FLUPHENAZINE HYDROCHLORIDE — Original Application (Upsher-Smith Laboratories, LLC)
FDA approved a generic version of fluphenazine hydrochloride through an original ANDA submission by Upsher-Smith Laboratories, LLC.